These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23382808)

  • 1. Functional roles of the non-catalytic calcium-binding sites in the N-terminal domain of human peptidylarginine deiminase 4.
    Liu YL; Tsai IC; Chang CW; Liao YF; Liu GY; Hung HC
    PLoS One; 2013; 8(1):e51660. PubMed ID: 23382808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probing the Roles of Calcium-Binding Sites during the Folding of Human Peptidylarginine Deiminase 4.
    Liu YL; Lee CY; Huang YN; Chen HY; Liu GY; Hung HC
    Sci Rep; 2017 May; 7(1):2429. PubMed ID: 28546558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional role of dimerization of human peptidylarginine deiminase 4 (PAD4).
    Liu YL; Chiang YH; Liu GY; Hung HC
    PLoS One; 2011; 6(6):e21314. PubMed ID: 21731701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis for Ca(2+)-induced activation of human PAD4.
    Arita K; Hashimoto H; Shimizu T; Nakashima K; Yamada M; Sato M
    Nat Struct Mol Biol; 2004 Aug; 11(8):777-83. PubMed ID: 15247907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetic characterization of protein arginine deiminase 4: a transcriptional corepressor implicated in the onset and progression of rheumatoid arthritis.
    Kearney PL; Bhatia M; Jones NG; Yuan L; Glascock MC; Catchings KL; Yamada M; Thompson PR
    Biochemistry; 2005 Aug; 44(31):10570-82. PubMed ID: 16060666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal structure of human peptidylarginine deiminase type VI (PAD6) provides insights into its inactivity.
    Ranaivoson FM; Bande R; Cardaun I; De Riso A; Gärtner A; Loke P; Reinisch C; Vogirala P; Beaumont E
    IUCrJ; 2024 May; 11(Pt 3):395-404. PubMed ID: 38656308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Interplay between the Dimer Interface and the Substrate-Binding Site of Human Peptidylarginine Deiminase 4.
    Lee CY; Lin CC; Liu YL; Liu GY; Liu JH; Hung HC
    Sci Rep; 2017 Feb; 7():42662. PubMed ID: 28209966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis for histone N-terminal recognition by human peptidylarginine deiminase 4.
    Arita K; Shimizu T; Hashimoto H; Hidaka Y; Yamada M; Sato M
    Proc Natl Acad Sci U S A; 2006 Apr; 103(14):5291-6. PubMed ID: 16567635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody discovery identifies regulatory mechanisms of protein arginine deiminase 4.
    Zhou X; Kong S; Maker A; Remesh SG; Leung KK; Verba KA; Wells JA
    Nat Chem Biol; 2024 Jun; 20(6):742-750. PubMed ID: 38308046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revamped role for approved drug: integrative computational and biophysical analysis of saquinavir's peptidyl arginine deiminase 4 inhibition for rheumatoid arthritis.
    Thirugnanasambandham I; Jupudi S; Roychowdhury P; Karri VVSR; Madhunapantula SRV; Singh SK; Subramaniyan V; Kuppusamy G
    Biochem J; 2024 Oct; 481(20):1379-1393. PubMed ID: 39312210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of GSK199 and GSK106 binding on protein arginine deiminase IV stability and flexibility: A computational approach.
    Zainal Fithri HH; Ibrahim Z; Ali EZ
    Comput Biol Chem; 2023 Dec; 107():107962. PubMed ID: 37847978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haloacetamidine-based inactivators of protein arginine deiminase 4 (PAD4): evidence that general acid catalysis promotes efficient inactivation.
    Knuckley B; Causey CP; Pellechia PJ; Cook PF; Thompson PR
    Chembiochem; 2010 Jan; 11(2):161-5. PubMed ID: 20014086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structures of human peptidylarginine deiminase type III provide insights into substrate recognition and inhibitor design.
    Funabashi K; Sawata M; Nagai A; Akimoto M; Mashimo R; Takahara H; Kizawa K; Thompson PR; Ite K; Kitanishi K; Unno M
    Arch Biochem Biophys; 2021 Sep; 708():108911. PubMed ID: 33971157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-peptidylarginine deiminase-4 antibodies at mucosal sites can activate peptidylarginine deiminase-4 enzyme activity in rheumatoid arthritis.
    Demoruelle MK; Wang H; Davis RL; Visser A; Hoang J; Norris JM; Holers VM; Deane KD; Darrah E
    Arthritis Res Ther; 2021 Jun; 23(1):163. PubMed ID: 34092252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetic, stereochemical, and structural effects of mutations of the active site arginine residues in 4-oxalocrotonate tautomerase.
    Harris TK; Czerwinski RM; Johnson WH; Legler PM; Abeygunawardana C; Massiah MA; Stivers JT; Whitman CP; Mildvan AS
    Biochemistry; 1999 Sep; 38(38):12343-57. PubMed ID: 10493802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational, kinetic, and NMR studies of the roles of conserved glutamate residues and of lysine-39 in the mechanism of the MutT pyrophosphohydrolase.
    Harris TK; Wu G; Massiah MA; Mildvan AS
    Biochemistry; 2000 Feb; 39(7):1655-74. PubMed ID: 10677214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific modification of the functional arginine residue in soybean trypsin inhibitor (Kunitz) by peptidylarginine deiminase.
    Takahara H; Okamoto H; Sugawara K
    J Biol Chem; 1985 Jul; 260(14):8378-83. PubMed ID: 3874206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysregulation of PAD4-mediated citrullination of nuclear GSK3β activates TGF-β signaling and induces epithelial-to-mesenchymal transition in breast cancer cells.
    Stadler SC; Vincent CT; Fedorov VD; Patsialou A; Cherrington BD; Wakshlag JJ; Mohanan S; Zee BM; Zhang X; Garcia BA; Condeelis JS; Brown AM; Coonrod SA; Allis CD
    Proc Natl Acad Sci U S A; 2013 Jul; 110(29):11851-6. PubMed ID: 23818587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a new class of inhibitors for the protein arginine deiminase type 4 (PAD4) by structure-based virtual screening.
    Teo CY; Shave S; Chor AL; Salleh AB; Rahman MB; Walkinshaw MD; Tejo BA
    BMC Bioinformatics; 2012; 13 Suppl 17(Suppl 17):S4. PubMed ID: 23282142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-PAD4 autoantibodies in rheumatoid arthritis: levels in serum over time and impact on PAD4 activity as measured with a small synthetic substrate.
    Pollmann S; Stensland M; Halvorsen EH; Sollid LM; Kvien TK; Fleckenstein B; Molberg O
    Rheumatol Int; 2012 May; 32(5):1271-6. PubMed ID: 21267570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.